Accel-Rx Portfolio Companies Secure $40 Million Follow-On Funding
Accel-Rx announced that three of its portfolio companies - Kisoji Biotechnology, Soundbite Medical Solutions and Zucara Therapeutics - have secured a total of $40 million CDN in follow-on funding to advance the development and commercialization of their technologies.